Exact Science anticipates $99M in revenue, 150% growth in 2016: 4 key notes

Madison, Wis.-based Exact Sciences — the makers of Cologuard — anticipates revenue between $34.9 and $25.4 million for the fourth quarter of fiscal year 2016.

Here's what you need to know.

1. For the year, Exact Sciences anticipates revenue between $99 million to 99.5 million, an increase of 150 percent from 2015.

2. The company said more than 9,500 providers ordered Cologuard for the first time during the fourth quarter; for the year, nearly 60,000 providers ordered the test — an 122 percent increase from 2015.

3. In June 2016, insurers covered 62 million more beneficiaries. As of Jan. 6, 2017, more than 163 million people are eligible to have their test covered.

4. Exact Sciences will report its complete figures during its February 2017 earnings call.

Copyright © 2022 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.

 

Featured Learning Opportunities

Featured Webinars

Featured Whitepapers

Featured Podcast